Skip to content

Philip Borsellino

2 papers in the library · 8 citations · publishing 2023-2024

Papers

The Clinical Potential of Dimethyltryptamine: Breakthroughs into the Other Side of Mental Illness, Neurodegeneration, and Consciousness

Psychoactives February 26, 2024 Frankie A. Colosimo, Philip Borsellino, Reese I. Krider et al. 8 citations

DMT, a naturally occurring psychedelic compound, promotes neuroplasticity—the brain's ability to remodel its neural connections—by stimulating neuritogenesis, the growth of new neuronal branches. It interacts with serotonergic, sigma-1, and trace amine-associated receptors and their signaling pathways. Evidence from animal models and clinical trials suggests DMT can improve mental well-being in depression, anxiety, and PTSD, and may aid learning, memory, and recovery from brain injuries. The compound's potential to enhance neurogenesis, particularly for neurodegenerative conditions, is also explored.

Ketamine and the Disinhibition Hypothesis: Neurotrophic Factor-Mediated Treatment of Depression.

Pharmaceuticals (Basel, Switzerland) May 12, 2023 Philip Borsellino, Reese I Krider, Deanna Chea et al.

Ketamine offers rapid and enduring relief for major depressive disorder and treatment-resistant depression, unlike standard antidepressants. This narrative proposes that depression stems from neuronal atrophy and synaptic disconnection rather than a monoamine imbalance. Ketamine, its enantiomers, and metabolites act through multiple pathways, including NMDAR inhibition and enhanced glutamatergic signaling. The disinhibition hypothesis suggests ketamine causes excitatory cortical disinhibition, releasing neurotrophic factors like BDNF, VEGF, and IGF-1, which repair neuro-structural abnormalities. Ketamine's efficacy is revolutionizing psychiatric treatment and understanding of mental illness.